Andrew Place, MD, PhD

Dr. Andrew Place is a pediatric oncologist at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center where he serves as Chief Medical Officer of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dr. Place completed his undergraduate studies at Swarthmore College majoring in Biology and subsequently received his MD and PhD degrees at the Geisel School of Medicine and Dartmouth College. He completed pediatric training at the Boston Combined Residency Program followed by pediatric Hematology/Oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute. Dr. Place is a physician-scientist investigating novel therapies for high-risk pediatric leukemia. He is a nationally recognized clinical trialist, who serves in leadership committees of several large consortia including the Dana-Farber Acute Lymphoblastic Leukemia (ALL) Consortium (Principal Investigator), the Therapeutic Advances in Childhood Leukemia Consortium (Chair, Steering and Prioritization Committee) and the Children’s Oncology Group (Vice Chair, Myeloid Disease Committee).  Dr. Place also served (2018-23) as the Chief Medical Officer of the Institutional Centers for Clinical and Translational Research at Boston Children’s Hospital.  Dr. Place’s research has focused on the design and implementation of early and late–phase trials for patients with acute leukemias.  He has either led or collaborated in the development of trials testing everolimus, selinexor, ribociclib, liposomal vincristine, pegaspargase, dasatinib, azacitidine and venetoclax in pediatric patients with both newly diagnosis and relapsed acute leukemia.  Dr. Place will be the Principal Investigator for the next upfront DFCI ALL Consortium study testing venetoclax in newly diagnosed children and adolescents with ALL.